We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Somanta Presents Data on Angiolix for Targeting Breast Cancer Stem Cells

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Somanta Presents Data on Angiolix for Targeting Breast Cancer Stem Cells"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Somanta Pharmaceuticals, Inc., a cancer stem cell company focused on in-licensing differentiated oncology compounds and anti-cancer agents, will present preclinical data on Angiolix, a humanized monoclonal antibody, that recognizes a migrating adhesion molecule called Lactadherin, at the academic community sponsored Stem Cells and Cancer conference March 2-7 in Keystone, Colorado.

Angiolix binds to Lactadherin, which is thought to cause a VEGF-independent integrin receptor signaling cascade that blocks vascular endothelial cell proliferation.

Accordingly, cancer stem cells can over-express VEGF and contribute to tumor vasculature growth needed to supply blood to cancer cells.

Somanta’s recent data suggests that tumor cells express Lactadherin and that Angiolix may be able to act to specifically target breast cancer stem cell and cause tumor regression by blocking the growth of tumor vasculature by its ability to neutralize Lactadherin-integrin receptor binding.

Angiolix has been shown to achieve more than 75% growth inhibition of human breast cancer growing as xenografts in mouse models.